Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
US Department of Justice
Federal Trade Commission
McKesson
Fish and Richardson
Chinese Patent Office
Farmers Insurance
Colorcon
US Army
Accenture

Generated: August 22, 2017

DrugPatentWatch Database Preview

STRATTERA Drug Profile

« Back to Dashboard

What is the patent landscape for Strattera, and what generic Strattera alternatives are available?

Strattera is a drug marketed by Lilly and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in STRATTERA is atomoxetine hydrochloride. There are fourteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the atomoxetine hydrochloride profile page.

Summary for Tradename: STRATTERA

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list8
Bulk Api Vendors: see list71
Clinical Trials: see list34
Patent Applications: see list1,064
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:STRATTERA at DailyMed

Pharmacology for Tradename: STRATTERA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly
STRATTERA
atomoxetine hydrochloride
CAPSULE;ORAL021411-001Nov 26, 2002DISCNNoNo► Subscribe► SubscribeY► Subscribe
Lilly
STRATTERA
atomoxetine hydrochloride
CAPSULE;ORAL021411-007Feb 14, 2005ABRXYesNo► Subscribe► SubscribeY► Subscribe
Lilly
STRATTERA
atomoxetine hydrochloride
CAPSULE;ORAL021411-004Nov 26, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
Lilly
STRATTERA
atomoxetine hydrochloride
CAPSULE;ORAL021411-008Feb 14, 2005ABRXYesNo► Subscribe► SubscribeY► Subscribe
Lilly
STRATTERA
atomoxetine hydrochloride
CAPSULE;ORAL021411-002Nov 26, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: STRATTERA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly
STRATTERA
atomoxetine hydrochloride
CAPSULE;ORAL021411-008Feb 14, 2005► Subscribe► Subscribe
Lilly
STRATTERA
atomoxetine hydrochloride
CAPSULE;ORAL021411-001Nov 26, 2002► Subscribe► Subscribe
Lilly
STRATTERA
atomoxetine hydrochloride
CAPSULE;ORAL021411-005Nov 26, 2002► Subscribe► Subscribe
Lilly
STRATTERA
atomoxetine hydrochloride
CAPSULE;ORAL021411-003Nov 26, 2002► Subscribe► Subscribe
Lilly
STRATTERA
atomoxetine hydrochloride
CAPSULE;ORAL021411-007Feb 14, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: STRATTERA

Drugname Dosage Strength RLD Submissiondate
atomoxetine hydrochlorideCapsules10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mgStrattera5/29/2007
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Accenture
McKesson
Fish and Richardson
Dow
Argus Health
Deloitte
McKinsey
Johnson and Johnson
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot